Australia's Starpharma falls on withdrawing marketing application for nasal spray

Starpharma Holdings

18/10/2024 05:26

** Shares of Starpharma Holdings  SPL.AX  fall as much as
2.2% to A$0.091, their lowest level since Sept. 11
    ** Biopharmaceutical co withdraws marketing authorisation
application for SPL7013 nasal spray with Australia's Therapeutic
Goods Administration
    ** SPL7013 is an antiviral spray for protection against
COVID-19 
    ** Co says withdrawal after a more than three-year
application and review process that consumed significant
internal resources
    ** About 1.5 mln shares change hands, 3 times the 30-day avg
of 478,000 shares
    ** Starpharma down 45.9% YTD    

 (Reporting by Nikita Maria Jino in Bengaluru)
 ((Nikita.Jino@thomsonreuters.com;))